Clinical Comparison between Paclitaxel Liposome (Lipusu®) and Paclitaxel for Treatment of Patients with Metastatic Gastric Cancer

Aim: To compare the efficacy and safety of paclitaxel liposome (Lipusu®) with paclitaxel in combination withtegafur and oxaliplatin in treating patients with advanced gastric cancer. Materials and
Methods: Patients withadvanced gastric cancer receiving chemotherapy were retrospectively collected, and divided into two groups.Patients in group A received paclitaxel liposomes at a dose of 135 mg/m2 on day 1 of each cycle, and patients ingroup B were given paclitaxel at the same dose with the same timing. All patients received tegafur at a dose of500 mg mg/m2 on days 1-5, and oxaliplatin at a dose of 80-100 mg/m2 on day 1 for 2 cycles (each cycle was 21 d intotal).
Results: Fifty-eight patients could be evaluated for efficacy. The overall response rate was 47% in groupA (14/30), and 46% in group B (13/28). Disease control rate was 73% in group A (22/30), and 71% in group B(20/28) (P>0.05). No significant differences were detected in hematologic and neurologic toxicities between thetwo groups (P>0.05). However, nausea, vomiting and hypersensitive reactions were significantly lower in groupA than in group B (P<0.05).
Conclusion: Paclitaxel liposomes are as effective as paclitaxel when combined withtegafur and oxaliplation in treating patients with advanced gastric cancer, but adverse reactions with paclitaxelliposomes are less common.